Berg Nutrition Brings a Unique Form of Pure Capsaicin Called aXivite to U.S. Marketplace
July 28, 2020 10:02 ET
|
Berg Nutrition
ANN ARBOR, Mich., July 28, 2020 (GLOBE NEWSWIRE) -- Berg Nutrition has been named the exclusive U.S. distributer of the branded ingredient, aXivite phenylcapsaicin, a synthetic, innovative form of...
Biotricity Launches Innovative Pain Management Product with NeuPath Health
March 10, 2020 08:00 ET
|
biotricity
REDWOOD CITY, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has launched its...
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
January 27, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...
Adynxx Reports Third Quarter 2019 Financial Results
November 14, 2019 06:00 ET
|
Adynxx, Inc.
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting
October 28, 2019 07:57 ET
|
Aptinyx Inc.
Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday,...
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience
October 15, 2019 08:46 ET
|
Aptinyx Inc.
EVANSTON, Ill., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
September 30, 2019 07:03 ET
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925
September 26, 2019 08:07 ET
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors
September 04, 2019 07:27 ET
|
Aptinyx Inc.
EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Endonovo Therapeutics Appoints Dr. Geoffrey Abrams of Stanford University to Its Scientific Advisory Board
August 30, 2019 09:00 ET
|
Endonovo Therapeutics Inc.
LOS ANGELES, Aug. 30, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Endonovo Therapeutics Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical®...